.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Julphar
US Department of Justice
Cantor Fitzgerald
Cerilliant
Daiichi Sankyo
Farmers Insurance
AstraZeneca
Deloitte
Healthtrust

Generated: June 26, 2017

DrugPatentWatch Database Preview

VIRAMUNE Drug Profile

« Back to Dashboard

What is the patent landscape for Viramune, and when can generic versions of Viramune launch?

Viramune is a drug marketed by Boehringer Ingelheim and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in VIRAMUNE is nevirapine. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the nevirapine profile page.

Summary for Tradename: VIRAMUNE

Patents:0
Applicants:1
NDAs:3
Suppliers / Packagers: see list3
Bulk Api Vendors: see list77
Clinical Trials: see list34
Patent Applications: see list4,715
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIRAMUNE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
VIRAMUNE
nevirapine
SUSPENSION;ORAL020933-001Sep 11, 1998AARXYesYes► Subscribe► Subscribe
Boehringer Ingelheim
VIRAMUNE XR
nevirapine
TABLET, EXTENDED RELEASE;ORAL201152-001Mar 25, 2011ABRXYesYes8,460,704► Subscribe ► Subscribe
Boehringer Ingelheim
VIRAMUNE
nevirapine
TABLET;ORAL020636-001Jun 21, 1996ABRXYesYes► Subscribe► Subscribe
Boehringer Ingelheim
VIRAMUNE XR
nevirapine
TABLET, EXTENDED RELEASE;ORAL201152-002Nov 8, 2012ABRXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIRAMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
VIRAMUNE
nevirapine
SUSPENSION;ORAL020933-001Sep 11, 19985,366,972*PED► Subscribe
Boehringer Ingelheim
VIRAMUNE
nevirapine
TABLET;ORAL020636-001Jun 21, 19965,366,972*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VIRAMUNE

Drugname Dosage Strength RLD Submissiondate
nevirapineExtended-release Tablets400 mgViramune XR6/21/2013
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
Julphar
Argus Health
Cerilliant
Cipla
Johnson and Johnson
Cantor Fitzgerald
Boehringer Ingelheim
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot